Clarus Therapeutics Holdings

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company was founded in 2004 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Borqs Technologies

Petros Pharmaceuticals

Can these penny stocks climb this coming week? The post 3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting

Kaleido Biosciences Inc

Powerbridge Technologies Co Ltd

Check these three penny stocks out as Musk tries to buy TWTR The post Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR

Clarus

Clarus Therapeutics Holdings' (CRXT) CEO Bob Dudley on Q4 2021 Results - Earnings Call Transcript

2021 net revenue increased 119% year-over-year to $14.0 million

Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes.

Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

Sphere 3D

Calithera Biosciences

Can these meme penny stocks under $3 make you money next month? The post 3 Hot Meme Penny Stocks to Watch Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Meme Penny Stocks to Watch Under $3 Right Now

Imperial Petroleum

Transocean

Check these Reddit penny stocks out for your watchlist right now The post Best Reddit Penny Stocks to Watch During Trading Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Reddit Penny Stocks to Watch During Trading Today

Denison Mines

Gevo

Are these trending penny stocks on your watchlist right now? The post 4 Trending Penny Stocks to Add to Your Watchlist Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Trending Penny Stocks to Add to Your Watchlist Right Now

JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions

Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer 32nd Annual Healthcare Conference, Tuesday, March 15, 2022, 10:00 a.m. ET.

Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients

Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate)

Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement

Clarus Therapeutics Announces $15 Million Private Placement

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions

Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)

Clarus Therapeutics' (CRXT) CEO Bob Dudley on Q3 2021 Results - Earnings Call Transcript

Third quarter 2021 revenue increased 93% year-over-year to $4.3 million

Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results

NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 18, 2021, after the market closes.

Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results

JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions

Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA

NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present at the 2021 Cantor Virtual Global Healthcare Conference, Monday, September 27, 2021, 10:40 a.m. ET.

Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

Clarus Therapeutics Holdings Inc (NASDAQ: CRXT) and Canada's McGill University have announced licensing agreement whereby Clarus will develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies. Coenzyme-Q10 (Ubiquinone) is synthesized in the inner membrane of mitochondria, a cellular organelle whose primary function is to produce the body's chemical energy.

Clarus Therapeutics, McGill University Ink Licensing Pact For Rare CoQ10-Associated Conditions

Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases

Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies

NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Monday, September 20, 2021, 2:05 p.m. ET.

News for Clarus Therapeutics Holdings Stock (CRXT)